GC Aesthetics Inc announces successful surgical and patient care results in its multi-centric safety and efficacy study for nipple reconstruction using the novel silicone implant, FixNip NRI.
The FixNip NRI – Nipple Reconstruction Implant is an implantable hypodermic, silicone implant specially designed for aesthetic improvement of the female nipple, according to the company in a media release.
Reconstruction of the breast Nipple-Areolacomplex (NAC) remains a significant challenge for surgeons in reconstructive surgery, and yet it is critical for long-term patient satisfaction.
“The interim results of the first in-human study confirm our assumptions regarding the safety of the device and the long-lasting projection of the nipple. This is another milestone in our ongoing efforts to improve and enhance the aesthetic outcome. It is very satisfying to see how the search for nipple-areola complex reconstruction, combined with the efforts of surgeons and innovators, has led to a solution that is easily utilized, safe and produces satisfying results.”
— Prof. Michael Scheflan, an expert in the field of aesthetic and reconstructive plastic surgerywho has been involved in the treatment, research, development, and implementation of advanced methods of plastic surgery
The product is designed with unique characteristics that mimic a natural nipple touch and look. This can help significantly to relieve the psychological burden and impaired quality of life for women treated with total or partial mastectomy, the release continues.
“FixNip is a disruptive innovation for breast reconstruction and specifically nipple restoration. During the first procedures, I can confirm the effectiveness and results. It can make a very meaningful difference for surgeons and patients. This prosthesis provides a natural solution that is maintained over time.
“The first tests in France are very encouraging, and complications are very rare. Patient feedback is excellent because it only requires one step, and a small scar that is safe for breast reconstruction.”
— Pr. Michael Atlan, French Plastic Surgeon leading the GCA multi-centric safety and efficacy pilot
“Breast reconstruction represents a substantial portion of the breast implant market, opening significant opportunities for this technology. We will be launching FixNip NRI in early 2022, in European Markets first.
GCA is excited to bring this revolutionary product to plastic surgeons and patients as part of a complete breast reconstruction solution, improving the lives of women and significantly raising the standards for breast surgery recovery.”
— Carlos Reis Pinto, CEO of GC Aesthetics
[Source(s): GC Aesthetics Inc, PR Newswire]
